GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)
In part two of our series, I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants. The post GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3) appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this…
We haven't written up this one. Labiotech has the full story — the link below goes straight to it.
